191 related articles for article (PubMed ID: 32460889)
1. Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer.
Takakusagi Y; Katoh H; Kano K; Anno W; Tsuchida K; Mizoguchi N; Serizawa I; Yoshida D; Kamada T
Radiat Oncol; 2020 May; 15(1):127. PubMed ID: 32460889
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer.
Sato H; Kasuya G; Ishikawa H; Nomoto A; Ono T; Nakajima M; Isozaki Y; Yamamoto N; Iwai Y; Nemoto K; Ichikawa T; Tsuji H;
Cancer Sci; 2021 Sep; 112(9):3598-3606. PubMed ID: 34107139
[TBL] [Abstract][Full Text] [Related]
3. Five-year clinical outcomes of scanning carbon-ion radiotherapy for prostate cancer.
Takakusagi Y; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Kamada T; Katoh H
PLoS One; 2024; 19(3):e0290617. PubMed ID: 38457424
[TBL] [Abstract][Full Text] [Related]
4. Carbon ion radiotherapy for prostate cancer with bladder invasion.
Miyasaka Y; Kawamura H; Sato H; Kubo N; Mizukami T; Matsui H; Miyazawa Y; Ito K; Nakano T; Suzuki K; Ohno T
BMC Urol; 2021 Aug; 21(1):106. PubMed ID: 34362355
[TBL] [Abstract][Full Text] [Related]
5. Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.
Kasuya G; Ishikawa H; Tsuji H; Nomiya T; Makishima H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Haruyama Y; Kobashi G; Tsujii H;
Cancer; 2016 Oct; 122(20):3225-3231. PubMed ID: 27351298
[TBL] [Abstract][Full Text] [Related]
6. Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.
Habl G; Uhl M; Katayama S; Kessel KA; Hatiboglu G; Hadaschik B; Edler L; Tichy D; Ellerbrock M; Haberer T; Wolf MB; Schlemmer HP; Debus J; Herfarth K
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):435-443. PubMed ID: 27084659
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks.
Nomiya T; Tsuji H; Maruyama K; Toyama S; Suzuki H; Akakura K; Shimazaki J; Nemoto K; Kamada T; Tsujii H;
Br J Cancer; 2014 May; 110(10):2389-95. PubMed ID: 24722181
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen dynamics after neoadjuvant androgen-deprivation therapy and carbon ion radiotherapy for prostate cancer.
Takakusagi Y; Oike T; Kano K; Anno W; Tsuchida K; Mizoguchi N; Serizawa I; Yoshida D; Katoh H; Kamada T
PLoS One; 2020; 15(11):e0241636. PubMed ID: 33156884
[TBL] [Abstract][Full Text] [Related]
9. Safety of Carbon-ion Radiotherapy for Prostate Cancer After Rectal Cancer Surgery.
Takakusagi Y; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Kamada T; Katoh H
Anticancer Res; 2023 Jun; 43(6):2691-2695. PubMed ID: 37247892
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: A retrospective study.
Takakusagi Y; Kawamura H; Okamoto M; Kaminuma T; Kubo N; Mizukami T; Sato H; Onishi M; Ohtake N; Sekihara T; Nakano T
PLoS One; 2019; 14(2):e0211370. PubMed ID: 30807581
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.
Jolnerovski M; Salleron J; Beckendorf V; Peiffert D; Baumann AS; Bernier V; Huger S; Marchesi V; Chira C
Radiat Oncol; 2017 Jun; 12(1):99. PubMed ID: 28622770
[TBL] [Abstract][Full Text] [Related]
13. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
[TBL] [Abstract][Full Text] [Related]
14. Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer.
Zhang Y; Li P; Yu Q; Wu S; Chen X; Zhang Q; Fu S
Radiat Oncol; 2019 Jun; 14(1):94. PubMed ID: 31164172
[TBL] [Abstract][Full Text] [Related]
15. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039
[TBL] [Abstract][Full Text] [Related]
16. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.
Jereczek-Fossa BA; Beltramo G; Fariselli L; Fodor C; Santoro L; Vavassori A; Zerini D; Gherardi F; Ascione C; Bossi-Zanetti I; Mauro R; Bregantin A; Bianchi LC; De Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):889-97. PubMed ID: 21277113
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
18. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
[TBL] [Abstract][Full Text] [Related]
19. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
20. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
